1Y Target$73.13Near-term target
5Y Target$86.87Compound horizon
10Y Target$127.70Long-dated conviction
FCF$1.3bTTM · 03/26C+FCF $1.3b — respectable but not differentiating · TTM computed from 4 most-recent quarters (TTM · 03/26).
Rev+49.3%TTM YoYARevenue +49.3% — hypergrowth, top decile
D/E0.11A-D/E 0.11 — conservative leverage, strong balance sheet
P/E17.0xB+P/E 17.0 — at or below S&P median, reasonable
PEG7.02DPEG 7.02 — very expensive; pricing in best-case scenarios
Why now
Gold · market cap $22.7b. Down 23% from 52-week high of $69.99 — deep drawdown territory. Revenue growing +49% — in hypergrowth territory. 8 sell-side analysts rate this a Buy with a mean 1-yr target of $73.13 (implying +36% upside).
Moat
Net margin 32% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 21% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 104% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Beta 1.49 implies above-market volatility — position-size to the drawdowns this name will produce in a market correction, not to its bull-case return. Commodity exposure — earnings power tracks the price of the underlying commodity, not management execution. A 15-20% move in the commodity reprices the equity well before fundamentals catch up.
Horizon
1-3 yr $73.13 (8-analyst consensus) — fundamentals + valuation re-rating. 5 yr $86.87 at ~10% CAGR — compounding case rests on the competitive position widening. 10 yr $127.70 if current growth sustains into durable earnings power.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See
terms and
methodology for full disclosures.